PerkinElmer Inc (PKI.N) agreed to purchase Caliper Life Sciences Inc (CALP.O) for $600 million to broaden its reach in molecular imaging and genomic detection technologies. The deal marks the biggest acquisition for PerkinElmer under Robert Friel, who became its chief executive in 2008. PerkinElmer, which sells scientific instruments, environmental safety monitoring products and medical testing equipment, said on Thursday it would pay $10.50 per share for Caliper, which represents a 42 percent premium over its closing share price of $7.39 on Wednesday. Caliper shares jumped 41 percent to $10.45 in premarket trading after the deal was announced.
PerkinElmer, Inc. is a provider of technology, services and solutions to the diagnostics, research, environmental and safety, industrial and laboratory services markets. Shares of PKI remained unchanged at $22.05. In the past year, the shares have traded as low as $20.67 and as high as $28.75. On average, 1159200 shares of PKI exchange hands on a given day and today's volume is recorded at 0.
Caliper Life Sciences, Inc. (Caliper) develops and sells products and services to the life sciences research community, a customer base that includes pharmaceutical and biotechnology companies, and government and other research institutions. Shares of CALP remained unchanged at $7.39. In the past year, the shares have traded as low as $3.31 and as high as $8.68. On average, 403535 shares of CALP exchange hands on a given day and today's volume is recorded at 8452235.
Source
